Amarillo Biosciences (OTCMKTS:AMAR – Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.
Insider and Institutional Ownership
23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 34.4% of Amarillo Biosciences shares are owned by company insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Amarillo Biosciences and Cyclacel Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amarillo Biosciences | 0 | 0 | 0 | 0 | 0.00 |
| Cyclacel Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Earnings & Valuation
This table compares Amarillo Biosciences and Cyclacel Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amarillo Biosciences | $20,000.00 | 0.00 | -$1.45 million | N/A | N/A |
| Cyclacel Pharmaceuticals | $750,000.00 | 5.75 | -$3.00 million | ($4.54) | -0.17 |
Amarillo Biosciences has higher earnings, but lower revenue than Cyclacel Pharmaceuticals.
Risk & Volatility
Amarillo Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500.
Profitability
This table compares Amarillo Biosciences and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amarillo Biosciences | -41,453.98% | N/A | -574.29% |
| Cyclacel Pharmaceuticals | N/A | -51.21% | -44.00% |
About Amarillo Biosciences
Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Receive News & Ratings for Amarillo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
